The newly public Evommune shared data showing that EVO301, an IL-18 targeting protein, cleared symptoms comparably to Regeneron and Sanofi’s mega-blockbuster in a mid-stage atopic dermatitis clinical ...
A staged approach for a patient decision aid (PDA) can help to deliver complex information in a patient-centered manner and ...
Chronic and highly burdensome, atopic dermatitis affects an estimated 223 million people worldwide, with onset commonly occurring in infancy and childhood. Rising awareness among parents, coupled with ...
The percentage of patients achieving total clearance of eczema lesions in a Phase 2b trial increased with prolonged rezpeg treatment.
Nektar Therapeutics (NASDAQ:NKTR) used an analyst and investor event to highlight 52-week results from the Phase 2b RESOLVE-AD trial of rezpegaldesleukin (ResPEG) in moderate-to-severe atopic ...
The event, the press release and the slides will also be available on the events section of the Nektar website at https://ir.nektar.com/events-and-presentations/events. A replay of the webcast will be ...
Nektar Therapeutics shares rose in premarket trading Tuesday after the company said it received positive data from its dermatitis drug study. Shares traded 13% higher ahead of the morning bell at $42.
INDICATIONS ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age. ZORYVE cream, 0.15%, is indicated for topical ...
Itchy and dry skin. Rashes and skin lesions affecting face, behind the knees, on the hands and feet and inside the folds of the elbows. The lesions due to scratching may be red, swollen, with cracking ...
Perioral dermatitis can be a frustrating condition and it can return without proper treatment. You may try prescription antibiotics or lifestyle changes. It can take weeks or months for the condition ...
Dermatitis herpetiformis is a bumpy, very itchy skin rash that’s caused by gluten sensitivity. In fact, about 10%-25% of people with celiac disease get dermatitis herpetiformis. Celiac disease is an ...
Amgen ends its rocatinlimab partnership, returning control to Kyowa Kirin, citing strategy changes, weaker Phase 3 results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results